The need for higher titer, higher producing cell lines, improved cell quality, lower production cost and accelerated development etc., are giving rise to new tools and technologies in upstream processing. Trends such as omics, modeling, gene editing, single-use technologies and digitalization are finding their way into biopharmaceutical companies’ process development strategies and toolkits. In addition to featuring these exciting trends, this year’s Upstream Processing will also feature a dedicated session on “Bioprocess Development Under Pandemic Conditions”, to address the challenges of manufacturing to meet global health, and adapting operations under such adverse conditions. 

Conferences Include:

Keynote Speakers:

David Maraldo, PhD, Vice President, Global Vaccines & Biologics Commercialization, Merck & Co., Inc.

Wolfgang Paul, PhD, Head, Upstream Process Science, UCB

Hong Liu, PhD, Biologics Process Development and Manufacturing Leader, Bill & Melinda Gates Medical Research Institute